JAC Advance Access originally published online on November 18, 2002
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Antimicrobial Chemotherapy (2002) 50, 953-964
© 2002 The British Society for Antimicrobial Chemotherapy
Comparability of antimicrobial susceptibility test results from 22 European countries and Israel: an external quality assurance exercise of the European Antimicrobial Resistance Surveillance System (EARSS) in collaboration with the United Kingdom National External Quality Assurance Scheme (UK NEQAS)
1 National Institute of Public Health and the Environment, Bilthoven; 6 Groningen University Hospital, Groningen, The Netherlands; 2 Institut Pasteur, Paris; 5 Institute de Vieille Sanitaire, Saint-Maurice, France; 3 PHLS, UK-NEQAS, London, UK; 4 Università di Verona, Verona, Italy
Received 12 February 2002; returned 2 May 2002; revised 10 July 2002; accepted 5 September 2002
The goal of this exercise was to organize external quality assurance (QA) of antibiotic susceptibility testing for laboratories participating in EARSS and to assess the comparability of susceptibility test results across countries, and guidelines. In September 2000, UK NEQAS distributed a set of three Streptococcus pneumoniae strains, two Staphylococcus aureus strains and one Streptococcus haemolyticus strain. Laboratories reported the guideline followed, the interpretation of the susceptibility test result and the MIC, if tested. In this study we considered results ‘concordant’ if the reported interpretation of the participating laboratory agreed with the designated interpretation of reference laboratories. Overall, 433 (92%) of 471 laboratories from 23 countries reported back. Of the 8685 tests that were assessed, 8322 (96%) were interpreted correctly by the participants. Concordance for detection of penicillin non-susceptibility in the three S. pneumoniae strains was 96%, 90% and 87%, respectively. Laboratories performed extremely well in detecting oxacillin resistance in the homogeneously methicillin-resistant S. aureus (MRSA) strain, but the concordance rate dropped from 100% to 77% in the heterogeneously resistant MRSA strain. Concordance for detection of teicoplanin resistance in the S. haemolyticus strain was 82%. We stratified concordance rates first for country and then for guideline used, but observed only minor differences among countries and guidelines. Quantitative methods yielding an MIC were more concordant than non-MIC methods for penicillin resistance in the S. pneumoniae strains (94% versus 79%). The NCCLS guideline was the most frequently followed, by 61% of laboratories from 19 countries. This exercise shows that, overall, countries participating in EARSS are capable of delivering susceptibility data of good quality. The comparability of susceptibility data for penicillin resistance in S. pneumoniae and for homogeneous methicillin resistance in S. aureus is satisfactory among European countries and across guidelines. However, we emphasize the importance of determining an MIC for suspected penicillin non-susceptible S. pneumoniae and for suspected glycopeptide non-susceptible S. aureus. Laboratories, particularly in some countries, may need to improve their capability to detect oxacillin resistance in heterogeneously resistant MRSA. For continuous external quality assessment we recommend that laboratories participate in national and international schemes with frequent distribution of control strains.
* Correspondence address. European Commission, DG SANCO, Directorate Public Health, Communicable, Rare and Emerging Diseases Unit, Eufo 3259, L-2920 Luxembourg. Tel: +352-4301-38221; Fax: +352-4301-33248; E-mail: stef.bronzwaer{at}cec.eu.int
Present address. Robert Koch-Institute, Berlin, Germany.
¶ Participating countries and national representatives in EARSS during 2000 are listed in the Acknowledgements.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  M. A. Borg, M. de Kraker, E. Scicluna, N. van de Sande-Bruinsma, E. Tiemersma, J. Monen, H. Grundmann, and on behalf of the ARMed Project members and collabo Prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in invasive isolates from southern and eastern Mediterranean countries J. Antimicrob. Chemother., December 1, 2007; 60(6): 1310 - 1315. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Oteo, E. Lazaro, F. J. de Abajo, F. Baquero, J. Campos, and Spanish Members of the European Antimicrobial Resi Trends in Antimicrobial Resistance in 1,968 Invasive Streptococcus pneumoniae Strains Isolated in Spanish Hospitals (2001 to 2003): Decreasing Penicillin Resistance in Children's Isolates J. Clin. Microbiol., December 1, 2004; 42(12): 5571 - 5577. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Bruinsma, K. G. Kristinsson, S. Bronzwaer, P. Schrijnemakers, J. Degener, E. Tiemersma, W. Hryniewicz, J. Monen, H. Grundmann, and on behalf of EARSS participants Trends of penicillin and erythromycin resistance among invasive Streptococcus pneumoniae in Europe J. Antimicrob. Chemother., December 1, 2004; 54(6): 1045 - 1050. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kahlmeter and D. F. J. Brown Resistance surveillance studies--comparability of results and quality assurance of methods J. Antimicrob. Chemother., December 1, 2002; 50(6): 775 - 777. [Full Text] [PDF]
|
|